

a:head bio AG secures additional private funding to advance its human brain tissue platform

Vienna, April 17, 2025 – a:head bio AG concluded a 7-digit funding round to drive the expansion of its disease model development and platform automation. The funding round was primarily backed by existing shareholders, with two new investors joining in 2025.

This investment will empower a:head to extend into a variety of indications with a strong focus on neurodegenerative diseases. The company also plans to increase the range of tissue types and create more sophisticated human brain models to enhance clinical relevance.

"This funding underscores investor confidence in our technology and strategic direction," says a:head bio AG CEO Oliver Szolar. "We are focused on expanding disease model capabilities and sophistication to deliver greater value."

"We are excited to fuel our efforts in automating our human brain organoid platform," says Josh Bagley, CSO of a:head. "This investment will support our goal of being able to produce and screen organoids with high quality at scale."

About a:head bio AG

a:head bio AG, is an Austrian biotech company uncovering novel CNS therapeutics by employing a proprietary drug development engine with true physiological relevance. Unlike the traditional strategies using molecular targets and animal models, the venture recreates central nervous system diseases in human brain tissue at scale. This biomedical revolution fuses cutting edge science using cell reprogramming, gene editing, state-of-the-art 3D culture technology, and digital biology. The company applies deep AI-driven analysis to uncover complex disease signatures and push disease model sophistication ahead to create unrivaled opportunities in CNS drug discovery.

Contact:

a:head bio AG, Dr.-Bohr-Gasse 7, VBC6, 1030 Vienna, Austria

Oliver Szolar, CEO

oliver.szolar@aheadbio.com

+43 1 3660519

www.aheadbio.com